To determine the role of mast cells in ischaemia-reperfusion (IR) injury to
skeletal muscle, W-f/W-f mast cell-deficient and their corresponding wild-
type mice were subjected to 70 min tourniquet ischaemia and 24 h reperfusio
n. As measured by nitroblue tetrazolium (NBT) staining, muscle viability wa
s 9% in wild-type and 94% in mast cell-deficient animals (p < 0.001). Assay
of residual lactate dehydrogenase activity within the injured muscle (p <
0.05) and histological examination confirmed the greater muscle necrosis in
treated wild-type than in treated mast cell-deficient mice. There was no s
ignificant difference in the degree of neutrophil infiltration, tissue myel
operoxidase content or water content of IR-injured muscle in the two mouse
phenotypes. To determine further the role of mast cells in IR injury, wild-
type mice were treated 30 min prior to reperfusion with an intraperitoneal
dose of either saline or the mast cell-stabilizing agent lodoxamide trometa
mol (2.5, 7.5, 25 or 75 mg/kg). Twenty-four hours after removal of the tour
niquet, saline-treated gastrocnemius muscle had a mean viability of 14% com
pared with 28% (p < 0.05) and 48% (p < 0.01) after 25 mg/kg and 75 mg/kg of
lodoxamide treatment, respectively. The ability of lodoxamide to stabilize
mast cells was confirmed by histological examination. Ischaemic muscle rep
erfused for 1 h showed much less degranulation of mast cells in mice pretre
ated with lodoxamide (50 mg/kg) than in saline-treated controls. These find
ings suggest that mast cells are a major source of mediators of necrosis in
IR injury to skeletal muscle. Copyright (C) 2000 John Wiley & Sons, Ltd.